Biotechnology

As ORIC Pharmaceuticals prepares to unveil pivotal clinical data in Madrid, the focus shifts to brain-penetrant lung cancer therapies and epigenetic modulation.

A new monoclonal antibody targeting the root cause of Graves' and thyroid eye disease could upend a market dominated by cumbersome infusions.

Basel-based biotech Nouscom just raised €120 million to fund a pivotal trial for NOUS-209, shifting oncology from treating tumors to intercepting them entirely.

By targeting the physical mechanics of tumors rather than biochemical pathways, Myosin Therapeutics aims to conquer glioblastoma and court investors in NYC.

Despite recent clinical setbacks, Alector's $75 million premium offering signals strong institutional faith in its blood-brain barrier technology.

Cyrano Therapeutics reports positive Phase 2 data for a repurposed asthma drug to treat post-viral smell loss, but regulatory hurdles loom for Phase 3.

As GLP-1 weight-loss drugs reshape consumption, Daesang Corporation's 450% allulose sales surge signals a massive shift in the industrial food supply chain.

By bringing on a veteran dealmaker with deep isotope supply chain expertise, Actinium is positioning its Ac-225 pipeline for big pharma's aggressive M&A wave.

As biomanufacturing scales to meet global demand, suppliers are locking in profits through recurring consumables and shifting their focus to Asian markets.

A new partnership between Neumarker and Cortica aims to end the trial-and-error approach in autism care by using AI to analyze complex brain wave data.

Transcripta Bio and Mayo Clinic are combining artificial intelligence and living patient data to map ALS, highlighting how institutions fuel precision medicine.

As Jasper Therapeutics completes Phase 2 enrollment for its novel IgAN therapy, we examine the structural shifts reshaping rare kidney disease treatment.

An N-of-3 pilot study reveals how Krystal Biotech's new intratumoral immunotherapy could replace lifelong surgeries with systemic immune clearance.

Amidst geopolitical headwinds, WuXi XDC's double win at the 2026 World ADC Awards highlights a relentless drive to dominate the bioconjugate supply chain.

Following a transformative $225 million capital injection, Lisata Therapeutics appoints a seasoned biotech M&A architect to its board of directors.

MindBio's new AI voice kiosk aims to disrupt industrial safety by detecting intoxication through speech, but regulatory and ethical hurdles loom large.

Phanes Therapeutics has advanced its first-in-class bispecific antibody into colorectal cancer trials, testing a novel mechanism to bypass systemic toxicity.

Pilatus Biosciences doses its first Hong Kong patient with PLT012, signaling a strategic shift toward metabolic immunotherapies and Asian clinical hubs.

A new Department of Energy pilot puts AI-designed plastic-eating enzymes to the ultimate industrial test inside a major California bottling facility.

Elion Therapeutics secures global rights to EL777, an inhaled antifungal aiming to prevent deadly infections in a growing immunocompromised population.